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Abstract There is emerging evidence for an under-
recognized hepatitis E virus (HEV) as a human pathogen.
Among different reasons for this neglect are the unsatis-
factory performance and under-utilization of commercial
HEV diagnostic kits; for instance, the number of anti-HEV
IgM kits marketed in China is about one-fifth of that of
hepatitis A kits. Over the last two decades, substantial
progress has been achieved in furthering our knowledge on
the HEV-specific immune responses, antigenic features of
HEV virions, and development of serological assays and
more recently prophylactic vaccines. This review will
focus on presenting the evidence of the importance of HEV
infection for certain cohorts such as pregnant women, the
key antigenic determinants of the virus, and immunoge-
nicity and clinical efficacy conferred by a newly developed
prophylactic vaccine. Robust immunogenicity, greater than
195-fold and approximately 50-fold increase of anti-HEV
IgG level in seronegative and seropositive vaccinees,
respectively, as well as impressive clinical efficacy of this
vaccine was demonstrated. The protection rate against the
hepatitis E disease and the virus infection was shown to be
100 % (95 % CI 75–100) and 78 % (95 % CI 66–86),
respectively.
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Introduction
Hepatitis E virus (HEV) is a major cause of acute hepatitis,
along with much better recognized hepatitis A virus [1]. It
is estimated that one-third of the world’s population has
been infected with the virus [2]. An estimated 14 million
symptomatic cases of HEV infection, with 300,000 deaths
and 5,200 stillborns, occur annually in the world, mainly in
developing countries of the Indian subcontinent, Southeast
and Central Asia, the Middle East, and northern and wes-
tern parts of Africa [3]. Hepatitis E refers to liver disease
caused by the HEV, a small non-enveloped virus with
single-stranded RNA genome. The virus, originally iden-
tified in 1983, has four distinct genotypes but with only one
serotype. Genotypes 1 and 2 infect humans only, whereas
genotypes 3 and 4 also infect pigs and several other
mammalian species.
There has been increased attention on HEV and the
associated disease in recent years owing to the increased
number of reports of autochthonous patients from many
developed countries. Vaccine development and better
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disease management are expected to emerge with increased
knowledge on pathogenesis and virology of HEV. This
review focuses on the hepatitis E disease, the pathogen
HEV, key antigenic determinants of HEV, and the devel-
opment and performance of a recombinant protein-based
prophylactic vaccine.
Hepatitis E disease and the virus
HEV as a human pathogen has been largely overlooked for
many years, except in certain outbreaks. In addition to
epidemics at different scales and during humanitarian cri-
ses among refugee populations without access to clean
water, sporadic cases and small clusters of HEV infections
have been recognized throughout the world in recent years.
Nelson et al. [4] recently reviewed the emerging evidence
of HEV infection as an under-recognized pathogen in
patients with hepatitis in developed countries.
Acute and chronic HEV infections among certain pop-
ulations, such as transplant recipients and other immuno-
compromised individuals including HIV/AIDS patients,
were also increasingly reported in recent years [4–6].
Evolution into chronic hepatitis was evidenced by persis-
tently elevated aminotransferase levels, which is quite
common during the post-surgery phase for organ trans-
plantation patients. Approximately 65.9 % of 85 patients
with HEV infection were identified to have chronic hepa-
titis after solid-organ transplantation due to immunosup-
pression [7]. In an earlier report, 8 out 14 patients had
developed chronic disease as a result of HEV infection plus
organ transplantation, as confirmed by persistently elevated
aminotransferase levels, serum HEV RNA, and histologic
features of chronic hepatitis [6]. Reducing the level of
immune suppression led to spontaneous viral clearance in
one-third of the patients [7]. Because of the unreliability of
antibody tests in this immunocompromised population,
direct molecular assay is necessary for diagnosis of HEV
infection.
Unique to HEV, high mortality among pregnant women
particularly during the third trimester distinguishes HEV
from other causes of acute viral hepatitis. During the large-
scale phase III trial of an HEV vaccine, the treatment
showed similar safety profiles and comparable immuno-
genicity among some women who had become pregnant
during the clinical trials. The retrospective analysis of the
safety and immunogenicity showed the real promise of the
vaccine in protecting this population which is most vul-
nerable to this virus [8].
Recent surveillance data suggested that in rural Ban-
gladesh acute hepatitis, most of it likely hepatitis E, is
responsible for approximately 10 % of pregnancy-associ-
ated deaths. If the death rates due to acute hepatitis are
representative of South Asia in general, as many as 10,500
maternal deaths each year in this region alone may be
attributable to hepatitis E and, moreover, could be pre-
vented with existing vaccines [9]. Two HEV vaccines have
gone through clinical evaluation with one having been
licensed recently in China. This underscores the impor-
tance of testing the vaccine among pregnant women and
could be truly life-saving once widely adopted for women
of child-bearing ages. The molecular basis for the grave
outcome of HEV infection among pregnant women is not
clear, although progress is being made by several labora-
tories across the globe working on the virology of HEV.
Though HEV does not grow well in cell culture, several
aspects of its biology and pathogenesis have been eluci-
dated using animal models and cell transfection studies,
and by analogy with other related viruses. The HEV is a
spherical, non-enveloped, single-stranded, positive-sense
RNA virus that is approximately 32–34 nm in diameter and
is the only member in the family Hepeviridae and genus
Hepevirus. While genotype 1 is predominantly associated
with large epidemics in developing countries, genotype 3
has recently emerged as a clinically significant pathogen in
developed countries. The clinical manifestations and the
laboratory abnormalities of hepatitis E are not distin-
guishable from those caused by other hepatitis viruses,
except the grave outcome among pregnant women. This
may have caused significant under-reporting of HEV as a
pathogen for hepatitis cases. In recent years, the number of
reported hepatitis E cases in China grew rapidly with more
HEV diagnostic kits being used in the clinical testing
laboratories. Interestingly, the growth rate of the reported
hepatitis E cases nicely matches the growth rate of the
diagnostic kit (anti-HEV IgM kit) sold on the Chinese
market (Fig. 1). Thus, the increase in hepatitis E cases
reflects better diagnosis with increased adoption of the anti-
HEV IgM diagnostic kit, rather than a true increase of HEV
infection or the disease.
Better understanding of the HEV virology and human
serological response would certainly help to improve the
disease management and likely facilitate the vaccine design
and development. The viral genome is a polyadenylated,
single-stranded, positive-sense RNA of about 7.2 kb with a
short non-coding region at both the 50 and the 30 ends. It
consists of three discontinuous and partially overlapping
open reading frames (ORFs). The largest ORF is ORF 1,
encoding non-structural proteins including methyltransfer-
ase, protease, helicase, and RNA-dependent RNA poly-
merase [10]. ORF2 encodes a structural protein—the only
protein of the viral capsid. The smallest ORF, ORF3,
encoding a phosphoprotein, was shown to be involved
extensively in viral evasion of the immune system and
regulation of viral replication and capsid assembly [11–18].
HEV is a non-cytopathic or weakly cytopathic virus, with
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immune-pathology playing an important role in the path-
ogenic mechanism of HEV infection. Not surprisingly, the
immune system directs the immune response mainly
against the capsid protein pORF2. Therefore, most of the
diagnostic kits are designed to detect the antibodies in sera
against HEV pORF2 epitopes. Better disease management
relies on robust-performing diagnostic kits to confirm the
viral infection.
Clinical biomarkers for diagnosis and lessons learned
from animal models
The lack of a standardized assay for clinical diagnosis is still
an issue, leading to likely under-reporting of HEV being the
pathogen for acute hepatitis cases. Even today, there is no
US Food and Drug Administration (FDA)-approved diag-
nostic kit for hepatitis E in the USA. Although there is a
World Health Organization (WHO) reference reagent for
antibody against HEV available through the National
Institute for Biological Standards and Control (NIBSC)
since 1997, it is not being commonly included in routine
testing or used as a standard for comparing different tests.
This reference reagent is human serum containing antibody
against HEV with assigned unitage at 100 U/ml; in this
paper, we refer to it as 100 Wu/ml. Even with the same set
of serum samples, the results could be quite different
depending on the anti-HEV kits used in the assay. As Zhang
et al. [19] indicated, the prevalence rate of antibodies
detected by another assay (IgG kit by GenLabs) using
antigen not including the E2s domain was much lower at the
plateau. In addition, although results obtained by the Wantai
E2-based anti-HEV IgG assay showed full conversion with
a robust plateau at 100 %, the seroconversion was delayed,
reaching an incomplete prevalence rate and with the prev-
alence rate declining after having peaked at a suboptimal
level for those infected animals [20]. Similarly with clinical
samples, comparative studies of the Wantai E2 assay and
GL peptide-based assay showed lower limits of detection
for these two anti-HEV IgG kits: 0.25 and 2.5 Wu/ml,
respectively. With a tenfold higher assay sensitivity, much
better results were obtained with the Wantai E2 kit:
(a) better detection for positivity in human sera from con-
firmed cases (98 vs. 56 %); (b) IgG levels remained positive
for longer periods of time post infection; and (c) resulted in
a substantially higher estimate of seroprevalence in blood
donors (16.2 vs. 3.6 %) with the same set of samples [21].
The main difference between the two assays is the antigen
used. The GL assay uses a mixture of peptides from both
pORF2 and pORF3 specified by the C-terminal of pORF2
(aa 613–660), C-terminal of pORF3 (aa 91–123), and the
full-length pORF3 [22]. As revealed by the cryo-electron
Fig. 1 Reported new cases of hepatitis E and sales of anti-HEV IgM
test kits in China (2003–2011). More reported hepatitis E cases due to
expanded utilization of the diagnostic kits as indicated by similar
trending of anti-HEV IgM kit consumption and number of reported
cases in China. The estimated number (1 unit = 1,000 tests) of HEV
diagnostic kit (anti-HEV IgM kit) sold in China on an annual basis
(data were courteously provided by Qiu ZX, Wantai Biologics,
Beijing). The jump of anti-HEV IgM testing numbers since 2009 can
be explained by the national policy that recent HEV infection had to
be excluded before issuing food health certificates since September
2009. The increased number of reported hepatitis E cases (data
source, Chinese Ministry of Health, http://www.moh.gov.cn/public
files//business/htmlfiles/mohjbyfkzj/s2907/index.htm) on an annual
basis for the past decade showed a similar trend with the increasing
number of anti-HEV IgM kits sold in the Chinese market
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microscopy (EM) and X-ray crystallographic structures
of the HEV virus-like particle (VLP), the protruding
E2s domain of viral capsid was clearly identified as the
region with immune-dominant epitopes as shown in Fig. 2
[23–27]. The lack of E2 domain in the GL assay resulted in
the inability of the GL assay to detect the immuno-dominant
epitopes in the dimeric E2 domain. In contrast, the E2 assay
uses the recombinant protein pE2, with ORF2 (aa 394–606),
correctly presenting the dimerized form of the E2s domain
with the conformational epitopes preserved just like those in
the virions.
Different kits were used to report the epidemiology data
in the field, causing a certain degree of confusion. When
different antigens were utilized, different assay specificity
and sensitivity were obtained, leading to different results or
even conclusions on previous exposure to HEV by detec-
tion of IgG antibodies [28–30]. Therefore, precautions are
needed when comparing the epidemiology data or animal
serological data obtained with different assays.
Infected monkeys were resistant to secondary attack of
symptomatic infection; however, only high levels of IgG
antibody could provide complete protection from second-
ary asymptomatic infection [31]. In a monkey model, the
IgG antibody response to the re-challenge varied from
unaffected to up to tenfold enhancement, whereas the IgM
response may or may not be detectable. These results
Fig. 2 Key antigenic determinants on HEV pORF2. a Antigenic and
assembly properties of truncated pORF2. b Crystal structure of HEV
capsid protein. Crystal structure of T = 1 HEV-VLP (PDB:2ZTN).
Mesh representations of dimeric E2s domains highlighted the
neutralizing epitopes against several neutralizing monoclonal anti-
bodies. c Key neutralizing epitopes on pORF2. All the identified
neutralizing sites were mapped in E2s domain [23, 36, 48, 57, 61]
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clearly demonstrated the different dynamics of IgG and
IgM during the primary and secondary HEV infections.
Therefore, four biomarkers—viral RNA, anti-HEV IgM,
anti-HEV IgG (at least fourfold rise), and low avidity of
anti-HEV IgG—are important in the diagnosis of HEV
infection, particularly for patients presenting with acute
hepatitis symptoms. This toolbox of genomic and immu-
nological assays is valuable in furthering our understanding
of the time course of HEV infection and the subsequent
hepatitis. The knowledge gained from animal serology or
clinical samples facilitated the design and development of a
prophylactic vaccine during preclinical and clinical
development of an efficacious vaccine [19]. In cases caused
by primary infection, there was a clear separation between
low avidity antibody produced soon after infection and
high avidity antibody produced later with a certain matu-
ration period [32–34]. Reinfection in humans are also
indicated by much high IgG avidity in the acute phase of
illness, with varying levels of IgM as reported in several
studies [33–36]. The difficulty encountered with the indi-
vidual markers in the diagnosis of hepatitis E could be
partially overcome by using a combination of all four
markers, i.e., viral RNA, anti-HEV IgM, rising IgG, and
IgG avidity [35].
Besides the aforementioned serological biomarkers,
anti-HEV IgA had been tested for its value in the diagnosis
of hepatitis E. In a study with 68 patients, complete sero-
positivity was reported for all patients using the anti-HEV
IgM or IgA assays [37]. In a more recent study, all three
antibody assays were performed for serum samples from 81
acute hepatitis patients. The seropositivity rate was 9.9, 7.4,
and 3.7 % for IgG, IgM, and IgA, respectively [38]. In both
studies, good correlation between the anti-HEV IgA and
anti-HEV IgM assays was observed, with both markers
being more stringent markers for viremic HEV infection
during the acute phase of HEV-associated hepatitis. Similar
kinetics for IgM and IgA were reported for HEV infection
[39], along with the longer detection period for IgM and
IgA as compared to serum HEV RNA for the same set of
samples [37]. Although anti-HEV IgA did not show addi-
tional value to anti-HEV IgM in the diagnosis of acute
HEV infection, further data are needed to understand the
diagnostic importance of anti-HEV IgA antibodies.
Key antigenic determinants of HEV
High immunoreactivity of serum samples was demon-
strated to recombinant pORF2, particularly to the dimer
form, but not to the monomer form. These samples include
sera from laboratory-infected animals including non-
human primates or from naturally infected individuals in
the acute or convalescent phase of HEV-induced hepatitis
[40, 41]. These results indicated the dominant immune
response to the HEV capsid protein during viral infection.
ORF2 encodes a single capsid protein of 660 aa, with the
N-terminal 112 residues involved in packaging of the viral
genome. The overall architecture of HEV capsid was elu-
cidated first from the cryo-EM structure of the VLP and
then the crystallographic structure of the VLPs of an
N-terminal and C-terminal truncated fragment (aa 14–608
or aa 112–608) of pORF2 [23–27]. The general architec-
ture of the viral capsid is as follows: (1) the capsid subunit
consists of partial homodimer of the structural protein; (2)
the S domain (aa 118–313) forms the virus shell, the P2 or
P domain (aa 454–606) forms the protrusion projecting
from the shell, and the P1 or M domain (aa 314–453)
contributes two-, three-, and fivefold icosahedral symmetry
of the virus capsid [26, 27]. The presence of the S domain
is essential to form the T = 1 or T = 3 icosahedral VLP. In
the absence of the S domain, the P1 and P2 domains were
predicted to form smaller particles [42, 43].
The detailed structure of the P2 and P1 domains and
their functions were elucidated by the bacterially expressed
peptides, E2s (aa 455–603), pE2 (aa 394–606), and p239
(aa 368–606). High resolution (\2 A˚) crystal structures of
the E2s domain (equivalent to the P2 domain) from
genotypes 1 and 4 revealed an intimate interaction at the
dimeric interface in the homodimer, happening in twofold
direction of VLP [42]. A segment of the 66-aa extension to
the N terminus of E2s (pE2) enabled the spontaneously
assembly into hexamers in solution with neutral pH. Thus,
the domain aa 394–458 is involved in the interaction
between the dimeric domain to form the protrusions pro-
jecting from the surface of the virus shell [24]. For fivefold
axial interaction, the region centered at Tyr-288 plays a key
role in the capsid assembly [36]. Peptide pE2 contains 66
additional residues, and p239 contains another additional
26 residues, in the P1 domain (Fig. 2). The antigenicity or
antibody binding activity of these peptides is quite similar
[23]. The 66-aa extension in the P1 domain appears to
stabilize the dimeric structure of pE2, rendering it a useful
diagnostic agent, whereas the additional 26-aa extension in
p239 results in the formation of multimeric VLP, rendering
it more suitable as a vaccine candidate with much enhanced
immunogenicity [24].
Overall structural features of the E2s domain were
observed for four different genotypes, albeit there were
some minor structural variations in the side chains of dif-
ferent residues. These observations are consistent with the
serotyping based on immune reactivity to conclude with a
single serotype for four different HEV genotypes [44]. The
detailed functional profiles of the two kinds of genotypes
represented by genotypes 1 and 2 for human infection only
and by genotypes 3 and 4 for zoonosis remain unclear. The
crystal structure of E2s, in complex with the Fab fragment
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of a neutralizing and protective monoclonal antibody 8C11,
indicates that aa 497 is involved in determining the host
specificity of the virus [44].
Experimental results indicated that human serum anti-
bodies against HEV protected people from serious illness
during outbreaks [45]. Furthermore, experimental HEV
infections in animal models elicited an antibody response
which results in protective immunity [46]. As with most
other viruses [47–53], the outer protrusions on the virion
surface of HEV, harboring major neutralizing and protec-
tive epitopes, are essential for host recognition [54]. Sev-
eral recombinant proteins containing the E2s domain have
been shown to induce protective immunity against liver
injury in animals and some in human studies by homolo-
gous and heterologous HEV infection [41, 45, 55–60].
Efforts were made to characterize the neutralization sites
located on the native virions or recombinant VLPs
as probed with a large panel of monoclonal antibodies
[61–67]. To date, all identified neutralizing sites were
conformational and were mapped in the E2s domain of
pORF2 and are composed with discontinuous peptide
stretches (Fig. 2).
On the basis of the knowledge on HEV virology, virus-
induced immune response, and epidemiology, various
protein-based vaccines with truncated versions of capsid
protein pORF2 (Fig. 2) were designed and tested in pre-
clinical models. Two of the vaccine candidates have
undergone clinical assessment with p239 being recently
licensed in China.
Clinical evaluation of a prophylactic vaccine
To develop a prophylactic vaccine, one needs to understand
as much as possible the disease course and the immune
response from the natural infection. Clinically, HEV
infection manifests in different ways from asymptomatic to
fulminant hepatitis. About 20 % of infections are symp-
tomatic in high disease endemic areas where genotype 1 is
the predominant type. Among those with symptomatic
hepatitis E disease, the probability of death is estimated at
approximately 20 % for cases involving pregnant women
and approximately 2 % for other cases [45, 68–71].
Symptomatic primary infection was shown to elicit a
strong antibody response with anti-HEV IgG reaching a
mean of 80.9 Wu/ml. Other types of infection, i.e.,
asymptomatic primary infection, symptomatic reinfection,
and asymptomatic reinfection, only induced a modest
antibody response of approximately 4 Wu/ml [19]. The
fact that anti-HEV IgG antibody response to symptomatic
reinfection and their peak ALT levels are both signifi-
cantly lower than those in symptomatic primary infection
suggested that pre-existing immunity limited the extent of
the infection in these patients (Zhu et al., personal
communication).
Recombinant VLPs, consisting of various lengths of the
HEV capsid protein pORF2, were prepared to mimic the
protective and neutralizing epitopes on the virion surface as
probed and defined by different monoclonal antibodies
(Fig. 2). These immunogens were designed to elicit pro-
tective immunity when injected into non-human primates
or human volunteers during preclinical tests and clinical
trials. The protective immunity conferred by an insect cell-
expressed vaccine candidate, rHEV (Fig. 2), was first
demonstrated in a phase II clinical trial conducted in Nepal,
where the endemic stain is genotype 1, with vaccine
against homologous genotype 1 strain [58]. Three vaccine
doses elicited complete seroconversion in all participants.
Although antibodies were undetectable in about half of
them 2 years later, the vaccine was highly efficacious
against symptomatic HEV infection for at least 2 years,
i.e., 96 % (95 % CI 86–99) [58].
The doubt whether hepatitis E vaccine is protective
against heterogenous virus infection in humans had been
eliminated by a phase III trial conducted in China. This
large-scale, randomized, controlled blinded clinical trial
involved 112,604 subjects belonging to the same Chinese
community described above, where the majority of HEV
isolated from patients are genotype 4 [59]. The recombi-
nant protein-based vaccine candidate, later branded as
Hecolin, contains 30 lg of HEV239 antigen encompass-
ing 368–606 aa of ORF2 (Fig. 2) of HEV genotype 1
expressed in Escherichia coli. Three shots of vaccination
elicited a robust antibody response with the anti-HEV IgG
lasting for at least 2 years in most subjects. The vaccine-
induced peak IgG antibody level was in-between that of
symptomatic primary infection and that of asymptomatic
infection [19].
Hecolin vaccine, with a three-dose regime, elicited a
robust immune response as indicated by the anti-HEV IgG
level, much higher that of a natural infection (15.0 Wu in
naı¨ve group post immunization vs. 1.9 Wu from asymp-
tomatic natural infection) as shown in Table 1. Hecolin
vaccine is highly protective for symptomatic HEV infec-
tion with efficacy of 100 % (95 % CI 72–100). More
importantly, over 90 % of the symptomatic HEV infection
cases in the placebo group were caused by heterogenous
genotype 4 [58]. The determination of protection antibody
level for symptomatic infection is prevented by the lack of
cases in the vaccine group. Similar to the observation made
in the Nepal trial of the GlaxoSmithKline vaccine, two
shots of Hecolin in 1 month induced immediate protec-
tion against hepatitis E for at least 5 months till the third
shot. Hence the use of this prophylactic vaccine in the rapid
control of an epidemic is justified.
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Additional properties of Hecolin and its performance
during this trial are summarized in Table 1. Adverse events
attributable to the vaccine were few and mild; within the
closely monitored reactogenicity subset, solicited system-
atic adverse events within 72 after each vaccination were
less than 20 % for both vaccinated group and placebo
controls. Yet the reported systematic adverse events of
the entire vaccinated cohort were only 2 % from both the
vaccinated and the control groups [59]. Interestingly, in the
duration of the study, we had the opportunity to observe
some pregnancy in patients in the vaccinated group, and
their newborn babies. All pregnant women went to full-
term childbirth and no spontaneous abortion was observed;
the babies were born without congenital abnormality [8].
Taken together, the findings showed that hepatitis E
vaccine is highly immunogenic and protective for symp-
tomatic infection caused by homologous or heterogenous
HEV. It can effectively lower, but not entirely eliminate,
the risk of asymptomatic infection, whereas it does confer
complete protection from symptomatic hepatitis E disease.
Both the virus breakthrough in vaccinated individuals and
the reinfection in individuals with naturally acquired
immunity are associated with a lower initial anti-HEV IgG
antibody level. The protection level of vaccine-induced
antibody has not been determined to date.
Conclusion and future perspective
This review summarizes the current understanding of the
HEV virology, the key neutralization sites on the surface of
the viral capsid, and the immunogenicity and clinical
efficacy of a newly developed human vaccine. Protective
immunity against hepatitis E can be obtained by natural
exposure to the virus as well as by vaccination. Whereas
the natural exposure to the virus left most individuals
unprotected against reinfection, vaccination with Hecolin
showed superior results with a robust immune response and
a virtually complete protective immunity against the dis-
ease in healthy adults. The value of vaccination in public
health could be further realized by lowering the number of
asymptomatic virus carriers who might be the reservoirs of
food-borne or water-borne outbreaks. The latter is espe-
cially meaningful in areas endemic for genotype 1 or 2
viruses because of their singular human host. It is also
expected that the vaccination should benefit high-risk
populations such as pregnant women, patients with chronic
liver diseases, and patients undergoing immunosuppressing
therapy. Hepatitis E infection, which could be prevented
with a vaccine, and the subsequent disease could be life-
threatening among those cohorts. Much efforts and well-
planned studies are needed to better understand the vaccine
safety and efficacy in these corresponding populations.
Further studies are also needed to determine the duration
of protection from vaccination, the need for boosters, and
its efficacy in preventing disease when administered after
exposure to HEV has occurred [72].
Although the vaccination can be an effective way to
dramatically lower the HEV infection rate and to reduce
the disease, the key prevention strategy to reduce disease
burden of hepatitis E is improving the overall sanitation to
root out the HEV in the water supply and food chains.
Unfortunately, this may not be realized in the hyper-
endemic areas. Two recombinant protein-based vaccine
candidates showed a good safety profile, high immunoge-
nicity, and high efficacy against symptomatic and/or
asymptomatic HEV infection. One of the candidates was
recently licensed in China [57–59]. A good post-launch
vaccination adoption strategy for an effective prophylactic
vaccine is expected to afford an effective means to reduce
Table 1 Safety, immunogenicity, and efficacy conferred by vaccination with Hecolin during a large-scale clinical trial
Property Performance Ref.
Safety In healthy adults:
• Most adverse events were mild; vaccine-related serious AEs had not been observed
• Rates of solicited local AEs were higher in the vaccine group than in the placebo group (13 vs. 7 %) and the rates
of solicited systemic AEs were not significantly different between the two groups (20 vs. 20 %)
• Reported AE of the entire immunized population was \2 % of both vaccine and placebo groups
In pregnant women:
• Appeared to be safe for mothers and fetus
[5, 53]
Immunogenicity Robust humoral response—Hecolin induced, almost completely seroconversion, and reached sevenfold higher
level of anti-HEV IgG (15 Wu/ml) than immunity induced by asymptomatic infection (1.9 Wu/ml)
[28]
Efficacy 100 % (72–100) against hepatitis E disease;
78 % (66–86) against HEV infection;
100 % (9–100) against hepatitis E disease after receiving two shots in 1 month
[28, 53]
AE adverse event
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the morbidity and mortality caused by HEV infection.
The first hepatitis E vaccine, Hecolin, was launched in
China in October 2012. The much-needed use of the
vaccine in countries outside China is hindered by the fact
that the hepatitis E vaccine is not on the priority vaccine
list of WHO prequalification. Evaluation of Hecolin in
high-risk cohorts, such as pregnant women, children, and
immunocompromised individuals, will be the focus of
future clinical studies while the vaccine is being adopted
for healthy adults on the basis of the current label
claims.
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